Stage IV Adrenocortical Carcinoma
Current Clinical Trials
Note: Some citations in the text of this section are followed by a level of
evidence. The PDQ editorial boards use a formal ranking system to help the
reader judge the strength of evidence linked to the reported results of a
therapeutic strategy. (Refer to the PDQ summary on Levels of Evidence for more
information.)
Temporary palliation of disseminated adrenocortical carcinomas can sometimes be
achieved with the chemotherapeutic agent mitotane. Although measurable partial
remissions are unusual and are reported in only 19% to 34% of cases, excellent
palliation of hormone symptoms is commonly observed.[1] Prolonged treatment
with mitotane, however, is often limited by gastrointestinal and neurologic
toxicity. Local recurrences and selected sites of metastatic disease can
sometimes be palliated surgically.[2]
Clinical trials such as ECOG-1879 and SWOG-8325 are appropriate and should be considered whenever possible,
especially phase I and II trials that evaluate newer chemotherapeutic and
biologic agents.[3-6] Palliative chemotherapy with cisplatin-based regimens
has produced objective responses in approximately 30% of patients
treated.[4,5,7,8] One study reported that doxorubicin produced objective
responses in 3 of 16 patients with poorly differentiated, nonhormone-producing
tumors but no responses in 15 patients whose disease did not respond to
mitotane.[3]
Use of both platinum-based chemotherapy and mitotane achieved a 48.6% objective response and median time-to-progression of 18 months in responders.[9][Level of evidence: 3iiDiv] In 10 of 72 patients, subsequent surgical resection was possible.
Standard treatment options:
- Chemotherapy with mitotane.[1]
- Radiation therapy to bone metastases.[10]
-
Surgical removal of localized metastases, particularly those that are
functioning.[2]
Treatment options under clinical evaluation:
- Cisplatin has been reported to produce beneficial effects in some selected
patients with metastatic disease.[7,8,11]
- Clinical trials of other chemotherapy regimens.[3-6]
Current Clinical Trials
Check for U.S. clinical trials from NCI's PDQ Cancer Clinical Trials Registry that are now accepting patients with stage IV adrenocortical carcinoma. The list of clinical trials can be further narrowed by location, drug, intervention, and other criteria.
General information about clinical trials is also available from the NCI Web site.
References
-
Lubitz JA, Freeman L, Okun R: Mitotane use in inoperable adrenal cortical carcinoma. JAMA 223 (10): 1109-12, 1973.
[PUBMED Abstract]
-
Pommier RF, Brennan MF: An eleven-year experience with adrenocortical carcinoma. Surgery 112 (6): 963-70; discussion 970-1, 1992.
[PUBMED Abstract]
-
Decker RA, Elson P, Hogan TF, et al.: Eastern Cooperative Oncology Group study 1879: mitotane and adriamycin in patients with advanced adrenocortical carcinoma. Surgery 110 (6): 1006-13, 1991.
[PUBMED Abstract]
-
Bukowski RM, Wolfe M, Levine HS, et al.: Phase II trial of mitotane and cisplatin in patients with adrenal carcinoma: a Southwest Oncology Group study. J Clin Oncol 11 (1): 161-5, 1993.
[PUBMED Abstract]
-
Hesketh PJ, McCaffrey RP, Finkel HE, et al.: Cisplatin-based treatment of adrenocortical carcinoma. Cancer Treat Rep 71 (2): 222-4, 1987.
[PUBMED Abstract]
-
Schlumberger M, Ostronoff M, Bellaiche M, et al.: 5-Fluorouracil, doxorubicin, and cisplatin regimen in adrenal cortical carcinoma. Cancer 61 (8): 1492-4, 1988.
[PUBMED Abstract]
-
Tattersall MH, Lander H, Bain B, et al.: Cis-platinum treatment of metastatic adrenal carcinoma. Med J Aust 1 (9): 419-21, 1980.
[PUBMED Abstract]
-
Chun HG, Yagoda A, Kemeny N, et al.: Cisplatin for adrenal cortical carcinoma. Cancer Treat Rep 67 (5): 513-4, 1983.
[PUBMED Abstract]
-
Berruti A, Terzolo M, Sperone P, et al.: Etoposide, doxorubicin and cisplatin plus mitotane in the treatment of advanced adrenocortical carcinoma: a large prospective phase II trial. Endocr Relat Cancer 12 (3): 657-66, 2005.
[PUBMED Abstract]
-
Percarpio B, Knowlton AH: Radiation therapy of adrenal cortical carcinoma. Acta Radiol Ther Phys Biol 15 (4): 288-92, 1976.
[PUBMED Abstract]
-
Haq MM, Legha SS, Samaan NA, et al.: Cytotoxic chemotherapy in adrenal cortical carcinoma. Cancer Treat Rep 64 (8-9): 909-13, 1980 Aug-Sep.
[PUBMED Abstract]
Back to Top
< Previous Section | Next Section > |